Astellas Collaborates with KaliVir to Develop and Commercialize VET2-L2

 Astellas Collaborates with KaliVir to Develop and Commercialize VET2-L2

Astellas Collaborates with KaliVir to Develop and Commercialize VET2-L2

Shots:

  • KaliVir to receive $56M as upfront & other payments supporting the research & preclinical activities of VET2-L2 & is eligible to receive $307M & $271M as development, regulatory & commercialization for VET2-L2 & second product, respectively along with royalties on sales of each licensed product
  • The alliance integrates KaliVir’s expertise in the development of oncolytic viruses with Astellas’ capabilities in advanced drug development & its global business experience, enabling both parties to develop new immuno-oncology therapies
  • VET2-L2 (IV) is an oncolytic vaccinia virus that destroys cancer cells & activates anti-cancer immunity through the expression of therapeutic transgenes

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BioSpectrum Asia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post